IL17A and acute lymphoblastic leukemia: Furthermore IL-17A in the peripheral blood was under investigation of causing potential resistance of B-ALL cells to daunorubicin through activation of Akt signaling, making Th17 cells a possible novel target for development of future B-cell ALL immunotherapy [18].